文献速递预防保健、筛查与疫苗慢病管理

SARS-CoV-2疫苗接种与心肌炎或心肌心包炎:基于人群的队列研究

SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study.
PubMed 文献 · BMJ · 2021-12-16

该研究基于丹麦全国人群,纳入12岁及以上个体4 931 775人,随访2020年10月1日至2021年10月5日,比较接种疫苗后0-28天与接种前未接种时期心肌炎或心肌心包炎的发生风险。结果显示,接种mRNA-1273与心肌炎或心肌心包炎风险显著增加相关,主要驱动于12-39岁人群;接种BNT162b2仅在女性中与风险显著增加相关。但接种后28天内心肌炎或心肌心包炎的绝对发生率较低,即使在年轻年龄组也是如此。

要点

  • 接种mRNA-1273疫苗后28天内心肌炎或心肌心包炎风险显著增加(aHR 3.92),12-39岁人群风险更高(aHR 5.24),绝对发生率为5.7/10万。
  • 接种BNT162b2疫苗后整体风险未显著增加(aHR 1.34),但女性中风险显著增加(aHR 3.73),绝对发生率1.3/10万。
  • 接种后28天内心肌炎或心肌心包炎的绝对发生率低,即使在年轻年龄组也较低,解读时应权衡SARS-CoV-2 mRNA疫苗接种的获益。

核心结论

  • 接种mRNA-1273与心肌炎或心肌心包炎风险显著增加相关,主要驱动于12-39岁人群;接种BNT162b2仅在女性中与风险显著增加相关。
  • 接种后28天内心肌炎或心肌心包炎的绝对发生率较低,即使在年轻年龄组也是如此;解读时应考虑SARS-CoV-2 mRNA疫苗接种的获益。

研究设计与样本

  • 基于人群的队列研究,在丹麦开展,纳入4 931 775名12岁及以上个体,随访自2020年10月1日至2021年10月5日。
  • 主要结局心肌炎或心肌心包炎定义为心肌炎或心包炎的医院诊断、肌钙蛋白水平升高和住院时间超过24小时的组合。
  • 采用Cox比例风险回归,以年龄为基本时间尺度,调整性别、合并症和其他潜在混杂因素,比较接种前随访时间与接种后0-28天随访时间(第一剂和第二剂)。

主要发现

  • 随访期间269名参与者发生心肌炎或心肌心包炎,其中108名(40%)为12-39岁,196名(73%)为男性。
  • 接种BNT162b2的3 482 295人中,48人在接种后28天内发生心肌炎或心肌心包炎,调整后风险比1.34(95%CI 0.90-2.00),绝对发生率1.4/10万(95%CI 1.0-1.8)。
  • 接种BNT162b2的女性调整后风险比3.73(95%CI 1.82-7.65),绝对发生率1.3/10万(95%CI 0.8-1.9);男性调整后风险比0.82(95%CI 0.50-1.34),绝对发生率1.5/10万(95%CI 1.0-2.2)。
  • 接种BNT162b2的12-39岁人群调整后风险比1.48(95%CI 0.74-2.98),绝对发生率1.6/10万(95%CI 1.0-2.6)。
  • 接种mRNA-1273的498 814人中,21人在接种后28天内发生心肌炎或心肌心包炎,调整后风险比3.92(95%CI 2.30-6.68),绝对发生率4.2/10万(95%CI 2.6-6.4)。

关键数值与推荐

  • 接种mRNA-1273的女性调整后风险比6.33(95%CI 2.11-18.96),绝对发生率2.0/10万(95%CI 0.7-4.8);男性调整后风险比3.22(95%CI 1.75-5.93),绝对发生率6.3/10万(95%CI 3.6-10.2)。
  • 接种mRNA-1273的12-39岁人群调整后风险比5.24(95%CI 2.47-11.12),绝对发生率5.7/10万(95%CI 3.3-9.3)。

临床怎么用

  • 在评估SARS-CoV-2 mRNA疫苗接种时,应告知接种后心肌炎或心肌心包炎的绝对风险较低,但mRNA-1273在年轻人群和BNT162b2在女性中的相对风险有所增加。
  • 临床医生应结合疫苗接种的获益与心肌炎或心肌心包炎的极低绝对风险进行个体化决策。

局限性

  • 需要更大规模的多国研究进一步调查疫苗接种后心肌炎或心肌心包炎在更小亚组中的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the association between SARS-CoV-2 vaccination and myocarditis or myopericarditis. DESIGN: Population based cohort study. SETTING: Denmark. PARTICIPANTS: 4 931 775 individuals aged 12 years or older, followed from 1 October 2020 to 5 October 2021. MAIN OUTCOME MEASURES: The primary outcome, myocarditis or myopericarditis, was defined as a combination of a hospital diagnosis of myocarditis or pericarditis, increased troponin levels, and a hospital stay lasting more than 24 hours. Follow-up time before vaccination was compared with follow-up time 0-28 days from the day of vaccination for both first and second doses, using Cox proportional hazards regression with age as an underlying timescale to estimate hazard ratios adjusted for sex, comorbidities, and other potential confounders. RESULTS: During follow-up, 269 participants developed myocarditis or myopericarditis, of whom 108 (40%) were 12-39 years old and 196 (73%) were male. Of 3 482 295 individuals vaccinated with BNT162b2 (Pfizer-BioNTech), 48 developed myocarditis or myopericarditis within 28 days from the vaccination date compared with unvaccinated individuals (adjusted hazard ratio 1.34 (95% confidence interval 0.90 to 2.00); absolute rate 1.4 per 100 000 vaccinated individuals within 28 days of vaccination (95% confidence interval 1.0 to 1.8)). Adjusted hazard ratios among female participants only and male participants only were 3.73 (1.82 to 7.65) and 0.82 (0.50 to 1.34), respectively, with corresponding absolute rates of 1.3 (0.8 to 1.9) and 1.5 (1.0 to 2.2) per 100 000 vaccinated individuals within 28 days of vaccination, respectively. The adjusted hazard ratio among 12-39 year olds was 1.48 (0.74 to 2.98) and the absolute rate was 1.6 (1.0 to 2.6) per 100 000 vaccinated individuals within 28 days of vaccination. Among 498 814 individuals vaccinated with mRNA-1273 (Moderna), 21 developed myocarditis or myopericarditis within 28 days from vaccination date (adjusted hazard ratio 3.92 (2.30 to 6.68); absolute rate 4.2 per 100 000 vaccinated individuals within 28 days of vaccination (2.6 to 6.4)). Adjusted hazard ratios among women only and men only were 6.33 (2.11 to 18.96) and 3.22 (1.75 to 5.93), respectively, with corresponding absolute rates of 2.0 (0.7 to 4.8) and 6.3 (3.6 to 10.2) per 100 000 vaccinated individuals within 28 days of vaccination, respectively. The adjusted hazard ratio among 12-39 year olds was 5.24 (2.47 to 11.12) and the absolute rate was 5.7 (3.3 to 9.3) per 100 000 vaccinated individuals within 28 days of vaccination. CONCLUSIONS: Vaccination with mRNA-1273 was associated with a significantly increased risk of myocarditis or myopericarditis in the Danish population, primarily driven by an increased risk among individuals aged 12-39 years, while BNT162b2 vaccination was only associated with a significantly increased risk among women. However, the absolute rate of myocarditis or myopericarditis after SARS-CoV-2 mRNA vaccination was low, even in younger age groups. The benefits of SARS-CoV-2 mRNA vaccination should be taken into account when interpreting these findings. Larger multinational studies are needed to further investigate the risks of myocarditis or myopericarditis after vaccination within smaller subgroups.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Husby A, Hansen JV, Fosbøl E, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ. 2021. PMID: 34916207. doi:10.1136/bmj-2021-068665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。